TY - JOUR
T1 - Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
AU - Merryman, Reid
AU - Rutherford, Sarah C.
AU - Ansell, Stephen
AU - Armand, Philippe
AU - Leonard, John P.
AU - Nastoupil, Loretta
AU - Smith, Sonali M.
AU - Timmerman, John
AU - Zelenetz, Andrew D.
AU - Gutierrez, Meghan
AU - Béguelin, Wendy
AU - Casulo, Carla
AU - Cerhan, James
AU - Green, Michael
AU - Kahl, Brad
AU - Kridel, Robert
AU - Link, Brian
AU - Maurer, Matthew J.
AU - Nadel, Bertrand
AU - Radtke, Andrea J.
AU - Luttwak, Efrat
AU - Salles, Gilles
AU - Sehn, Laurie
AU - Pasqualucci, Laura
AU - LaCasce, Ann S.
N1 - Publisher Copyright:
© 2026 American Society of Hematology
PY - 2026/3/10
Y1 - 2026/3/10
N2 - Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
AB - Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
UR - https://www.scopus.com/pages/publications/105031367921
U2 - 10.1182/bloodadvances.2025018079
DO - 10.1182/bloodadvances.2025018079
M3 - Comment/debate
C2 - 41337699
AN - SCOPUS:105031367921
SN - 2473-9529
VL - 10
SP - 1591
EP - 1602
JO - Blood Advances
JF - Blood Advances
IS - 5
ER -